Assembly Biosciences (ASMB) EBT (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly EBT of -$11.7 million for Q1 2026, down 17.17% year-over-year from -$14.1 million in Q1 2025, and down 152.95% quarter-over-quarter from $22.1 million in Q4 2025.
Assembly Biosciences (ASMB) EBT (2010 - 2026) Analysis & Trends
Assembly Biosciences' EBT history runs 17 years deep, the most recent figure standing at -$11.7 million for Q1 2026.
- In Q1 2026, EBT fell 17.17% year-over-year to -$11.7 million; the TTM figure through Mar 2026 stood at -$9.0 million (up 77.91% YoY), while the FY2025 annual figure was -$6.1 million, up 84.64% from the prior year.
- EBT for Q1 2026 stood at -$11.7 million, down from $22.1 million in the prior quarter.
- The five-year high for EBT was $22.1 million in Q4 2025, with the low at -$24.7 million in Q2 2022.
- The 5-year median for EBT is -$10.9 million (2023), against an average of -$12.7 million.
- The sharpest annual moves came in 2025 and 2026: EBT soared 312.18% in 2025, then retreated 17.17% in 2026.
- Assembly Biosciences' EBT stood at -$24.2 million in 2022, then surged by 54.75% to -$10.9 million in 2023, then increased by 4.74% to -$10.4 million in 2024, then soared by 312.18% to $22.1 million in 2025, then sank by 152.95% to -$11.7 million in 2026.
- Business Quant data shows ASMB's EBT at -$11.7 million in Q1 2026, $22.1 million in Q4 2025, and -$9.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.86 Mn |
| Mar 31, 2026 | -11.70 Mn |
| Dec 31, 2025 | 22.09 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -10.20 Mn |
| Mar 31, 2025 | -9.98 Mn |
| Dec 31, 2024 | -10.41 Mn |
| Sep 30, 2024 | -9.61 Mn |
| Jun 30, 2024 | -10.75 Mn |
| Mar 31, 2024 | -9.08 Mn |
| Dec 31, 2023 | -10.93 Mn |
| Sep 30, 2023 | -14.42 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -19.27 Mn |
| Dec 31, 2022 | -24.15 Mn |
| Sep 30, 2022 | -23.40 Mn |
| Jun 30, 2022 | -24.70 Mn |
| Mar 31, 2022 | -23.25 Mn |
| Dec 31, 2021 | -63.72 Mn |
| Sep 30, 2021 | -26.96 Mn |